CoChat
Sign Up
Cited by 123Pharmaceutical industry and healthcareGlobal Public Health Policies and EpidemiologyPolitical Influence and Corporate Strategies

Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.

Peppercorn, Jeffrey, Blood, Emily, Winer, Eric, Partridge, Ann·2007·Cancer
DOI 10.1002/cncr.22528
Open this paper in CoChat — free account

Abstract

BACKGROUND: Since 1992, pharmaceutical industry support has surpassed National Institutes of Health funding for clinical research in the United States. In this study, the authors sought to evaluate the impact of this shift in funding from public to private sponsors on the nature of published breast cancer clinical research. METHODS: All published breast cancer clinical trials from 2003, 1998, and 1993 were reviewed from 10 select English-language medical journals to evaluate pharmaceutical involvement over time and the association between sponsorship, trial design, and results. Clinical studies that reported disease-specific outcomes from medical therapy for breast cancer were eligible for analysis. Pharmaceutical involvement was defined as reported pharmaceutical industry funding, provision of drug, and/or authorship for each publication. RESULTS: In total, 140 eligible studies were identified, including 45 studies that were published in 1993, 39 studies that were published in 1998, and 56 studies that were published in 2003. Among those, 67 publications (48%) reported pharmaceutical industry involvement, 36 publications (26%) had at least >/=1 pharmaceutical industry author, And 100 publications (71%) were considered positive. Pharmaceutical involvement was identified in 44% of the studies published in 1993, in 38% of the studies published in 1998, and in 58% of the studies published in 2003. Pharmaceutical authorship was reported in 22% of the 1993 studies, in 21% of the 1998 studies, and in 34% of the 2003 studies. For studies that were published in 2003, those that reported pharmaceutical involvement were more likely to be positive (84% vs 54%; P = .02; Fisher exact test), to be single-arm studies (66% vs 33%; P = .03), and to evaluate metastatic disease (72% vs 46%; P = .06). CONCLUSIONS: Pharmaceutical involvement in published clinical breast cancer research may affect study design, focus, and results. Further research is warranted, including analysis of unpublished studies, to evaluate the impact of increasing pharmaceutical industry involvement on clinical research.

Integrity signals

Registry

Crossref · 10.1002/cncr.22528

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Peppercorn, J., Blood, E., Winer, E., & Partridge, A.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Dana-Farber Cancer Institute (US)
  • Sanofi (France) (FR)
Corresponding author
Peppercorn, Jeffrey
ORCID
Venue
Cancer
Publisher
Wiley
Published
2007-02-26
Volume
109
Issue
7
Pages
1239-1246
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
DOI
10.1002/cncr.22528
OpenAlex
W2052494740
Cited by
123
References
26
Citations by year
2025: 5 · 2024: 2 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 5 · 2015: 7 · 2014: 8 · 2013: 7 · 2012: 8
FWCI
11.63
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmaceutical industry and healthcare
  • Social Sciences › Business, Management and Accounting › Organizational Behavior and Human Resource Management › Global Public Health Policies and Epidemiology
  • Social Sciences › Business, Management and Accounting › Strategy and Management › Political Influence and Corporate Strategies
Keywords
pharmaceutical industry sponsorship, breast cancer clinical trials, conflicts of interest, trial design, single-arm studies, metastatic breast cancer, research funding sources
MeSH terms
Antineoplastic Agents, Authorship, Breast Neoplasms, Clinical Trials as Topic, Drug Evaluation, Drug Industry, Humans, Publishing, Research Support as Topic, Treatment Outcome, Biomedical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review